Cite
Fluorofenidone attenuates renal fibrosis by inhibiting lysosomal cathepsin‑mediated NLRP3 inflammasome activation.
MLA
Zheng, Linfeng, et al. “Fluorofenidone Attenuates Renal Fibrosis by Inhibiting Lysosomal Cathepsin‑mediated NLRP3 Inflammasome Activation.” Experimental and Therapeutic Medicine, vol. 27, no. 4, Feb. 2024, p. 142. EBSCOhost, https://doi.org/10.3892/etm.2024.12430.
APA
Zheng, L., Mei, W., Zhou, J., Wei, X., Huang, Z., Lin, X., Zhang, L., Liu, W., Wu, Q., Li, J., & Yan, Y. (2024). Fluorofenidone attenuates renal fibrosis by inhibiting lysosomal cathepsin‑mediated NLRP3 inflammasome activation. Experimental and Therapeutic Medicine, 27(4), 142. https://doi.org/10.3892/etm.2024.12430
Chicago
Zheng, Linfeng, Wenjuan Mei, Jing Zhou, Xin Wei, Zhijuan Huang, Xiaozhen Lin, Li Zhang, et al. 2024. “Fluorofenidone Attenuates Renal Fibrosis by Inhibiting Lysosomal Cathepsin‑mediated NLRP3 Inflammasome Activation.” Experimental and Therapeutic Medicine 27 (4): 142. doi:10.3892/etm.2024.12430.